Extended limb preservation employing an optimization strategy for stabilization. - in collaboration with prof
Ended Project Grant Awarded Last action
- Award ID
- R43HL158398
- Recipient
-
Tissue Testing Technologies LLC UEI ZSY2J1RRALT5
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,018,353
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Funding
-
- $678,807.02 Federal
- $339,546.00 Non-federal
- Place of performance
- South Carolina, USA
Award details come from USAspending.gov.
Description
Brandacher at johns hopkins university we plan to improve upon the currently most used clinical method of limb preservation, namely hypothermia at 0 to +4°C. We will build upon our base preservation formulation, unisol™, that has been shown to preserved whole large animals below +10°C for 6- 8H after total blood replacement with unisol™ with normal functions upon return to physiological conditions. We have also shown that unisol™ can maintain blood vessel function for at least 6 days at both -7°C and +4°C and that mouse hearts stored at 4°C for 18 hours in unisol™ have a significantly faster return of heart function than hearts stored in the gold standard hypothermic heart preservation solution celsior (HTK). Encouraged by these results we propose evaluation of unisol supplemented with reagents targeting oxidation, apoptosis (enhancers of stress tolerance) and metabolism (metabolic rate inhibition) in 2 specific aims using human skeletal myoblasts and vascular endothelial cells to select optimal reagent concentrations in vitro and a RAT forelimb transplant model to evaluate the best supplement formulations developed in the in vitro studies. The lead in vitro assay will be alamarblue, however outcomes will be checked using alternative assays including trypan blue, live/dead stain and MTT assay. Apoptosis will be evaluated if significant losses of metabolic activity are observed 1 to 2 days after return to physiologic culture conditions. The in vivo studies will evaluate the best formulations from the in vitro studies over 3 days of hypothermic storage by transplantation model. Controls limbs will be preserved in unisol™ and HTK. We anticipate that the supplemented formulation will maintain viability and function of limbs for up to 36 hours, a considerable improvement over all current practice methods. This innovation will not only increase storage time, IT will also provide the opportunity for more closely matched recipients and potentially induction of tolerance. Furthermore, we are improving on the most tried and true method for hypothermic limb storage in clinical practice that is relatively inexpensive and easy to ship by air. Demonstration of =24 hours of hypothermic storage with >70% retention of limb functions will be considered to be a successful demonstration of feasibility for progression to a phase II sbir proposal for further evaluation in large animal models and EX vivo human limb evaluation post-preservation.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$285 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $339,546 | $0 | |
| Original award | $339,546 | $339,546 |
Quick answers
Who received award R43HL158398?
R43HL158398 was awarded to Tissue Testing Technologies LLC by National Heart Lung and Blood Institute (National Institutes of Health) on April 1, 2021.
How much is award R43HL158398 worth?
$1,018,353 has been obligated on R43HL158398: $678,807 in federal funding and $339,546 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award